Bimekizumab demonstrated sustained improvements in pain and fatigue in patients with axial spondyloarthritis achieving early control of disease activity: 3-year results from two phase 3 studies and their open-label extension

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.